Papers/PMID:36849161
The effect of micro-particle curcumin on chronic kidney disease progression: the MPAC-CKD randomized clinical trial.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2023The record
2 findings · 1 compound · 2 endpoints · 2 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
2 findings
curcumin — no detected effect on health-related quality of life
Evidence strength: moderate.FindingNull result“Table 3 a shows that treatment with curcumin had no significant effect on quality of life as measured by the Physical or Mental Component Summary Scores of the SF-36 Health Survey.”
Quoted verbatim from The effect of micro-particle curcumin on chronic kidney disease progression: the MPAC-CKD randomized clinical trial.. - Study
- RCT
- Duration
- 6 months
- Dose
- 90 mg micro-particle curcumin once daily vs matching placebo
- Population
- Adults with albuminuric chronic kidney disease (eGFR 15 to 60 mL/min/1.73 m2); 6-month follow-up
The effect of micro-particle curcumin on chronic kidney disease progression: the MPAC-CKD randomized clinical trial.2023PMID:3684916110.1093/ndt/gfad037Industry fundedPermalink
curcumin — no detected effect on estimated glomerular filtration rate
Evidence strength: moderate.FindingNull result“Similarly, the 6-month change in eGFR did not differ significantly between the curcumin and placebo groups (mean between-group difference –0.22 mL/min/1.73 m2, 97.5% CI –1.38 to 0.95, P =.68).”
Quoted verbatim from The effect of micro-particle curcumin on chronic kidney disease progression: the MPAC-CKD randomized clinical trial.. - Study
- RCT
- Duration
- 6 months
- Dose
- 90 mg micro-particle curcumin once daily vs matching placebo
- Population
- Adults with albuminuric chronic kidney disease (eGFR 15 to 60 mL/min/1.73 m2) on stable ACE inhibitor or ARB where appropriate; 6-month follow-up
Effect -0.22 mean difference, 95% CI -1.38 to 0.95
The effect of micro-particle curcumin on chronic kidney disease progression: the MPAC-CKD randomized clinical trial.2023PMID:3684916110.1093/ndt/gfad037Industry fundedPermalink